Literature DB >> 2934542

Characterization of 5-hydroxytryptamine receptors in rat stomach fundus.

B V Clineschmidt, D R Reiss, D J Pettibone, J L Robinson.   

Abstract

1-Arylpiperazines (MK-212, quipazine, m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine) caused a serotonin (5-HT) receptor-mediated contraction of rat fundic strips. m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine had high affinity for the receptor but little efficacy, whereas quipazine and MK-212 had lesser affinity and much greater efficacy. 5-HT itself was the most potent (EC50 = 6-9 nM) agonist and possessed the greatest affinity (KA = 9.7 nM). Assessment of receptor occupancy vs. functional response (as well as receptor alkylation studies) demonstrated a very small, if any, receptor reserve in this tissue. Several arylquinolizines were found to be competitive antagonists of 5-HT-induced contraction, the most potent being L-653,267 and rauwolscine (KB values = 1.9 and 3.8 nM). Clozapine, trazodone and propranolol were identified as less potent, competitive antagonists, whereas various ergolines (including LY 53857), L-646,462 (cyproheptadine analog) and mianserin were noncompetitive. Potent 5-HT2 receptor antagonists (pirenpirone and ketanserin) antagonized only weakly or were without effect against 5-HT, indicating that the fundic 5-HT receptor is not of the 5-HT2 subtype. Because the fundic receptor has high affinity for 5-HT (as does the 5-HT1 binding site in brain tissue), the possible correspondence of the fundic 5-HT receptor with the 5-HT1 recognition site in rat brain cortex was considered. 5-HT, the nonindole agonists (1-arylpiperazines) and the competitive antagonists all competed with [3H]-5-HT for the 5-HT1 site. However, all compounds except 5-HT had Hill slopes significantly less than 1.0, precluding a valid comparison with dissociation constants derived pharmacologically in the fundus. With respect to having a high affinity for 5-HT, the 5-HT receptor mediating contraction of fundic smooth muscle resembles the 5-HT1 recognition site (as defined in brain tissue by radioligand binding), but identity remains unproven.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2934542

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  22 in total

1.  Characterization of 5-HT3 and 'atypical' 5-HT receptors mediating guinea-pig ileal contractions in vitro.

Authors:  R M Eglen; S R Swank; L K Walsh; R L Whiting
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist.

Authors:  D W Bonhaus; L A Flippin; R J Greenhouse; S Jaime; C Rocha; M Dawson; K Van Natta; L K Chang; T Pulido-Rios; A Webber; E Leung; R M Eglen; G R Martin
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

3.  Functional characterization and m-RNA expression of 5-HT receptors mediating contraction in human umbilical artery.

Authors:  F Lovren; X F Li; J Lytton; C Triggle
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

4.  Effect of SB 200646A, a 5-HT2C/5-HT2B receptor antagonist, in two conflict models of anxiety.

Authors:  G A Kennett; F Bailey; D C Piper; T P Blackburn
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

5.  Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle.

Authors:  G S Baxter; O E Murphy; T P Blackburn
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  Characterization of the 5-hydroxytryptamine receptor mediating the positive inotropic response in guinea-pig isolated left atria.

Authors:  N Lattimer; P Gupta; K F Rhodes
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

7.  Differential regulation of rat peripheral 5-HT(2A) and 5-HT(2B) receptor systems: influence of drug treatment.

Authors:  M J Enguix; L Sánchez; M Villazón; J Brea; H Tristán; H J Caruncho; M I Cadavid; M I Loza
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-07-12       Impact factor: 3.000

8.  Modulation of non-adrenergic non-cholinergic inhibitory neurotransmission in rat gastric fundus by the alpha 2-adrenoceptor agonist, UK-14,304.

Authors:  R A Lefebvre; G J Smits
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

9.  In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.

Authors:  G A Kennett; M D Wood; F Bright; J Cilia; D C Piper; T Gager; D Thomas; G S Baxter; I T Forbes; P Ham; T P Blackburn
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

10.  Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924.

Authors:  G J Sanger
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.